| Literature DB >> 35814515 |
Kirubakaran K Renganathan1, Anand Ramamurthy2, Sheeba Jacob3, Anil Tharigopula4, Anil Vaidya5, Mahesh Gopashetty6, Anand Khakar7.
Abstract
Graft verus host disease (GVHD) following Liver transplantation is rare life threatening complication with very high mortality rate around 85%. Due to increased recognition of this condition management approach is rapidly evolving due to newer diagnostic methods and drugs. Etiology, risk factors, pathogenesis, preventive strategies, management approach and newer drugs are discussed. We present our experience of 2 cases from a large cohort of 1052 Liver transplant operations over a decade.Entities:
Keywords: ATG, Anti thymocyte globulin; BD, Twice a day; CMV, Cytomegalovirus; CODIS, Combined DNA Index System; DBD, Donation after brain death; DCLD, Decompensated chronic liver disease; DNA, Deoxy ribonucleic acid; EBV, Ebstein bar virus; G-CSF, Granulocyte colony stimulating factor; GVHD, Graft versus host disease; HLA, Human Leukocyte antigen; HPS, Hepatopulmonary syndrome; HRS, Hepatorenal syndrome; IL, Interferon; IVIG, Intravenous immunoglobulin; JAK, Janus kinase; LT, Liver transplantation; MAD CAM, Mucosal addressin cell adhesion molecule; MDR, Multi drug resistant; MELD, Model for end stage liver disease; NAFLD, Non Alcoholic fatty liver disease; NASH, Non Alcoholic steatohepatitis; POD, Post operative day; QD, quaque die, stands for once a day; STR-PCR, Single tandem repeat polymerase chain reaction; chain reaction; combined DNA index system; deceased donor liver transplantation; graft versus host disease; single tanden repeat polymerase
Year: 2022 PMID： 35814515 PMCID： PMC9257876 DOI： 10.1016/j.jceh.2022.03.009
Source DB: PubMed Journal: J Clin Exp Hepatol ISSN： 0973-6883